Tewari Disha, Rawat Kalpana, Bisht Amisha, Almoyad Mohammad Ali Abdullah, Wahab Shadma, Chandra Subhash, Pande Veena
Department of Biotechnology, Kumaun University, Bhimtal, Uttarakhand, India.
Computational Biology & Biotechnology Laboratory, Department of Botany, Soban Singh Jeena University, Almora, Uttarakhand, India.
J Biomol Struct Dyn. 2024;42(24):13953-13970. doi: 10.1080/07391102.2023.2279281. Epub 2023 Nov 3.
Leishmaniasis is one of the most neglected parasitic diseases worldwide. The toxicity of current drugs used for its treatment is a major obstacle to their effectiveness, necessitating the discovery and development of new therapeutic agents for better disease control. In parasites, N-Myristoyltransferase (NMT) has been identified as a promising target for drug development. Thus, exploring well-known medicinal plants such as and their phytochemicals can offer a diverse range of treatment options, potentially leading to disease prevention and control. To assess the therapeutic potential of these compounds, their ADMET prediction and drug-likeness properties were analyzed. The top 4 compounds were selected which had better and significantly low binding energy than the reference molecule QMI. Based on the binding energy score of the top compounds, the results show that Isonimocinolide has the highest binding affinity (-9.8 kcal/mol). In addition, a 100 ns MD simulation of the four best compounds showed that Isonimocinolide and Nimbolide have good stability with LmNMT. These compounds were then subjected to MMPBSA (last 30 ns) calculation to analyze protein-ligand stability and dynamic behavior. Nimbolide and Meldenin showed lowest binding free energy i.e. -84.301 kJ/mol and -91.937 kJ/mol respectively. DFT was employed to calculate the HOMO-LUMO energy gap, global reactivity parameters, and molecular electrostatic potential of all hit molecules. The promising results obtained from MD simulations and MMPBSA analyses provide compelling evidence for the potential use of these compounds in future drug development efforts for the treatment of leishmaniasis.Communicated by Ramaswamy H. Sarma.
利什曼病是全球最被忽视的寄生虫病之一。目前用于治疗该病的药物的毒性是影响其疗效的主要障碍,因此需要发现和开发新的治疗药物以更好地控制疾病。在寄生虫中,N-肉豆蔻酰基转移酶(NMT)已被确定为一个有前景的药物开发靶点。因此,探索诸如[具体植物名称缺失]等知名药用植物及其植物化学物质可以提供多种治疗选择,有可能实现疾病的预防和控制。为了评估这些化合物的治疗潜力,分析了它们的ADMET预测和类药性质。选择了前4种化合物,它们比参考分子QMI具有更好且显著更低的结合能。基于顶级化合物的结合能得分,结果表明异诺米西诺内酯具有最高的结合亲和力(-9.8千卡/摩尔)。此外,对四种最佳化合物进行的100纳秒分子动力学模拟表明,异诺米西诺内酯和印楝素与利什曼原虫NMT具有良好的稳定性。然后对这些化合物进行MMPBSA(最后30纳秒)计算,以分析蛋白质-配体的稳定性和动态行为。印楝素和梅尔登宁显示出最低的结合自由能,分别为-84.301千焦/摩尔和-91.937千焦/摩尔。采用密度泛函理论计算所有命中分子的最高占据分子轨道-最低未占据分子轨道能隙、全局反应性参数和分子静电势。分子动力学模拟和MMPBSA分析获得的有前景的结果为这些化合物在未来治疗利什曼病的药物开发努力中的潜在应用提供了有力证据。由拉马斯瓦米·H·萨尔马传达。